DNLI stock forecast, quote, news & analysis
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases... Show more
Denali Therapeutics (DNLI) Stock Analysis: AVLAYAH Launch Momentum Meets a Catalyst-Rich Pipeline
Key Takeaways
- DNLI traded near $19.87 in early November, up roughly 2% over the trailing 30 days from about $19.45 in early October, a modest move below the 10% threshold.
- Third-quarter 2026 results showed AVLAYAH (tividenofusp alfa) net product revenue of $17.8 million in its second full commercial quarter, with Q4 2026 guidance of $30.0 million to $32.0 million.
- The company reported Q3 GAAP EPS of $0.37 and net income of $70.1 million, lifted by a one-time roughly $194 million gain from the sale of a Priority Review Voucher.
- Analyst sentiment remains constructive: consensus rating of "Strong Buy" with average 12-month price targets in the mid-$30s, and Guggenheim reiterated DNLI as a top pick after results.
- Near-term catalysts include December 2026 Phase II MoMeNtum data in multifocal motor neuropathy and continued execution on AVLAYAH reimbursement and launch uptake.
- The broader trend is mixed: shares are up about 35% over the past year but down double digits over the trailing three months.
- For additional detail on this ticker, explore Price Targets, Earnings, and Forecast pages.
- Discover how automated strategies are tracking this and other names through Trending AI Robots.
Current Market Snapshot
Denali Therapeutics shares have traded in a relatively narrow band over the past month, hovering in the high-teens to low-$20s range. The stock entered early November with a lift following its third-quarter earnings report but remains well below its 52-week high. With a market capitalization of roughly $3.1 billion, DNLI is followed primarily for its blood-brain barrier delivery platform and the commercial ramp of its first approved product rather than for near-term profitability. Over the trailing year the stock is up approximately 35%, though it has pulled back by double digits over the past three months, reflecting the volatility typical of clinical-stage and newly commercial biotechs.
Denali Therapeutics (DNLI) Business Overview and Competitive Position
Denali Therapeutics is a South San Francisco-based biopharmaceutical company focused on discovering and developing therapies for neurodegenerative and lysosomal storage diseases. Its core differentiator is its Transport Vehicle (TV) technology, which is designed to deliver large-molecule therapies across the blood-brain barrier—a hurdle that historically prevents most medicines from reaching brain tissue. The company pursues this through three franchises: Enzyme TV, Oligonucleotide TV, and Antibody TV.
The most advanced program is AVLAYAH (tividenofusp alfa), an enzyme replacement therapy that received FDA accelerated approval in March 2026 for the neurologic manifestations of Hunter syndrome, making it the first approved medicine to use transferrin-receptor delivery across the blood-brain barrier. The pipeline also includes investigational programs for Sanfilippo syndrome type A, frontotemporal dementia, Alzheimer's disease, Parkinson's disease, and Pompe disease. Investors follow DNLI for the combination of a newly commercialized product and a deep neurology pipeline.
Recent Developments Driving DNLI
Third-quarter 2026 results, reported on November 3, were the central event of the period. AVLAYAH generated $17.8 million in net product revenue in its second full commercial quarter, and management guided fourth-quarter net product revenue to $30.0 million to $32.0 million. The company reported GAAP EPS of $0.37 and net income of $70.1 million, which included a one-time gain of roughly $194 million from the sale of a rare pediatric disease Priority Review Voucher.
Reimbursement progress has been a key supporting factor. Commercial coverage has expanded to more than 70% of U.S. commercial insured lives, up from over 50% in the prior quarter, and a permanent J-code took effect on October 1, 2026, simplifying billing and reimbursement. In late October, AVLAYAH was also recognized with a 2026 Prix Galien USA award as Best Biotechnology Product.
Post-earnings analyst activity has been broadly supportive. Guggenheim reiterated DNLI as a top pick and maintained a Buy rating, while several firms reaffirmed Buy ratings with price targets well above the prevailing share price. The company ended the quarter with approximately $1.0 billion in cash and marketable securities, providing a substantial runway to fund its clinical programs.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies drawn from the platform's broader ecosystem of hundreds of AI-powered bots that trade thousands of tickers. Only the top-performing and most relevant bots appear in this section, giving users a focused view of strategies currently gaining traction. These bots vary in approach, timeframe, and performance metrics, so investors can compare models aligned with different trading styles and risk preferences. For those interested in how systematic, data-driven strategies are approaching names like DNLI and the wider market, the page offers a useful starting point for further research.
2026 Outlook and What Investors Should Watch
Looking ahead, the most immediate catalyst is the December 2026 top-line readout from the Phase II MoMeNtum study evaluating claseprubart in multifocal motor neuropathy. Continued execution on AVLAYAH's commercial ramp—including the fourth-quarter revenue guidance range—will also be closely monitored as a test of the product's launch trajectory and reimbursement momentum.
Into 2027, investors are expected to track the planned Biologics License Application for zafinofusp alfa in Sanfilippo syndrome type A, initial data from the Phase I DNTH212 study expected in the first quarter, and top-line results from Part A of the Phase III CAPTIVATE study in chronic inflammatory demyelinating polyneuropathy toward year-end 2027. Macroeconomic conditions, clinical-trial outcomes, and competitive dynamics in the rare-disease and neurology space remain key variables that could influence sentiment and valuation. These factors are informational considerations rather than investment recommendations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
DNLI's RSI Oscillator recovers from oversold territory
The RSI Indicator for DNLI moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 21 of the 26 cases the stock moved higher. This puts the odds of a move higher at 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on DNLI as a result. In 65 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for DNLI just turned positive on October 20, 2026. Looking at past instances where DNLI's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.
Following a +3.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNLI advanced for three days, in 206 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 62 cases where DNLI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
DNLI moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for DNLI moved below the 200-day moving average on October 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNLI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
DNLI broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for DNLI entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. DNLI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.841) is normal, around the industry mean (3.498). P/E Ratio (-7.067) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (2.300) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNLI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company
Industry Biotechnology